This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zimmer Biomet (ZBH) Receives FDA Nod for ROSA Hip System
by Zacks Equity Research
The recent FDA go-ahead for Zimmer Biomet's (ZBH) ROSA Hip System will aid surgeons perform robotically-assisted direct anterior total hip replacement surgery.
Zimmer Biomet (ZBH) Recovery Rate Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) sees slower recovery amid the emergence of a new strain of coronavirus in a number of markets, including Japan.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.
Zimmer Biomet (ZBH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 3.26% and 2.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand
by Zacks Equity Research
Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Zimmer Biomet (ZBH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest In Globus Medical (GMED) Now
by Zacks Equity Research
Strong first-quarter performance by the U.S. Spine and Enabling Technologies business contributed to Globus Medical's (GMED) top line.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again
by Urmimala Biswas
Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.
5 MedTech Stocks to Gain in 2021 as Base Business Recovers
by Urmimala Biswas
These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Zimmer (ZBH) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.
Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up
by Zacks Equity Research
Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 13.25% and 5.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.
Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
McKesson (MCK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.